雄岸科技(01647.HK)訂框架協議 擬組合營拓大麻二酚產品等業務
雄岸科技(01647.HK)公布,與Libosoils LLC訂戰略合作框架協議。根據協議,公司及Libosoils 擬於美國成立一間合營公司以共同發展工業大麻業務,雄岸科技將佔合營公司不少於70%股權。
合營公司將通過直接投資、合作或收購等方式,使合營公司在美國俄勒岡州擁有大麻二酚(CBD)年產量不低於25噸的提取加工工廠;及合營公司將與俄勒岡州當地農戶及政府建立良好關係,推進工業大麻在俄勒岡州的種植和加工的產能和質量,建立更好的原材料基礎;及積極向全球推廣合營公司的CBD產品。
本協議為期5年,在合作期間公司將作為Libosoils在俄勒岡州CBD提取加工工廠項目的唯一合作伙伴。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.